One billion people suffer from preventable, treatable diseases around the world
********************************************************************************
-----------------------------------------------------------------------------------
Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
The worldwide pharmaceutical industry is joining the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in calling on the G-8 nations the importance of neglected diseases as a global health threat and a major strain on the economic viability and educational development of communities worldwide.
The newly formed Alliance urged G-8 to finance successful treatment and prevention programs, to support innovative strategies that address the challenging health gaps in developing countries, and to fund research and development to develop improved diagnostic, treatment and prevention options.
Most international attention is focused on HIV/AIDS, tuberculosis, malaria and global health security. However, neglected tropical diseases - most of which are preventable and treatable - remain major causes of death and disability worldwide. These diseases receive less funding and less attention while they decrease productivity, negatively affect quality of life and increase poverty throughout the developing world.
*********************************************************************************
India's Hepatitis B Virus Drug Market Will Grow Ten-Fold by 2012
*********************************************************************************
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian hepatitis B virus drug market will grow ten-fold by 2012, from $1.7 million in 2007 to $17 million in 2012. According to the new Emerging Markets report entitled Hepatitis B Virus in India, this growth will be fueled by a growing awareness of the hepatitis B virus and the growth of individual wealth among India's urban middle and upper class.
Additionally, the report finds that the number of prevalent cases of chronic hepatitis B virus in India (30.6 million in 2007) is three times that of the United States, France, Germany, Italy, Spain, United Kingdom and Japan combined. However, both diagnosis rates and drug treatment rates in India are extremely low.
**********************************************************************************
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
*****************************************************************************************
Decision Resources also finds that the Chinese hepatitis B virus drug market will more than double by 2012, from $340 million in 2007 to $800 million in 2012. Both nucleoside/nucleotide analogues (NAs) and immunomodulators will experience strong double-digit growth, contributing to a robust 18 percent annual growth of the total market.
According to the new Emerging Markets report entitled Hepatitis B Virus in China, the greatest contributor to the growth of the Chinese hepatitis B drug market is the sheer size and nature of the epidemic in China- approximately 80 million Chinese people have chronic hepatitis B. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term growth in this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
BIOPRENEURS BITES from California Takshila University - To learn more about this author, visit Ryan Baidya's Website.
Like this article? Share it with your friends
 |
Related Articles |
|
 Talking In Media Morse Code
|
| |
Keep in mind, you want a couple of sound bites that you can pepper into the conversation, but you definitely do not want your entire conversation to be a series of sound bites.
|
|
What is Obama -The Politepreneur(c) - California Takshila University
|
| |
OBAMA, the politepreneur, is neither 100% African, nor 100% European nor 100% Mongolian (Asian). He is 100% AMERICAN -a race that comprise of all the genetics-material of the world - An entrepreneur in Politics.
...
|
|
The Men Behind MySpace: How Chris DeWolfe and Tom Anderson First Met
|
| |
 “It sounds crazy,” says Chris DeWolfe, “but even in the first plan that I wrote up, I mentioned AOL, Yahoo! and Hotmail, knowing we would be big. And it’s crazy to think that it happened.”
|
|
One Copy at a Time: Kinko’s Takes Off
|
| |
 Orfalea had been a student at USC when he noticed a copy machine in the school library. He realized that few people had access to the new technology and decided to do something about it. With a $5,000 loan from the ...
|
|
Lesson #3: Mix Things Up
|
| |
 When Puck first began considering expanding his operations overseas in Japan, he claims he was drawn to the country because he loved “the culture, the food, the politeness of the people and the fact that I’ll always...
|
 |
Related Businesses - Evan Elite Authors |
|
David Barr
David Barr is the President of Venture Opportunities, Inc. David has been a professional business broker/intermediary since 1980 focusing on General Business Brokerage and Mergers and Acquisitions representing client transaction value from $400,000 to $20,000,000. Mr. Barr has handled the sale of over four hundred and fifty companies. David earned a university degree from the State University of New York majoring in economics and business.
David holds the Mergers and Acquisition Master Intermediary and the Certified Business Intermediary designations from the International Business Brokers Association. He is also a Senior Business Analyst and a Texas licensed Real Estate Agent. For more information about David and Venture Opportunities, visit www.bizdealmaker.com. - Visit David Barr's Website |
|
The Evan Elite Authors program is currently in beta phase. For details please contact us.
|
|
|
Ryan Baidya
(Visit Ryan's Website)
Dr. Ryan Baidya is an entrepreneur a
business strategist and who has 12+ years
of experience in biotech. He launched
several biotech and high-tech businesses
in Silicon Valley/USA, and Tokyo/Japan.
He founded BioZak and BioZak-Infobase, and
served as one of the founding management.
Prior to that he was with Genprobe, ,
HyseQ; and GeneAsia. He serves as an
advisor to Golden-Embryo, Pune/India; and
KZAISoft corp., Durgapur/India. He gave
numerous lectures on life sciences and
bio-business topics at conferences,
primarily in USA, and Japan. He authored
articles, patents, and commentaries. Dr.
Baidya received his MS from IIT Kanpur,
PhD from the University of California,
Santa Cruz and MBA from the San Jose State
University, CA.
Currently he teaches at California
Takshila University.
|
|
|
|
![[Get Copyright Permissions]](http://license.icopyright.net/images/icopy-w.gif){kind=small}
